Get Clinical Trial Updates
Newsletter

Stay informed about our clinical trials and ongoing research. Sign up to receive our email newsletter.

Sign Up Now
Clinical Trials for Relapsed Cancer
ACCT

For patients with relapsed, refractory, or recurrent cancer, early phase clinical trials may be a treatment option.

Relapsed Cancer Clinical Trials

Affiliations and Consortia - Cloned

Liying Chen, PhD, and Kimberly Stegmaier, MD in a lab

Researchers at Dana-Farber/Boston Children's collaborate with doctors and researchers around the world to provide advanced care in more specialties and subspecialties, more expertise in every facet of care for cancer and blood disorders, and more cutting-edge treatment options. Thanks in part to these collaborations, we're introducing promising new drugs and opening worldwide clinical trials that break new ground across the spectrum of cancer and blood disorders — like our protocols targeted for relapsed acute lymphoblastic leukemia, molecular profiling of brainstem gliomas, bone marrow transplantation for dyskeratosis congenita, and immunotherapy for relapsed neuroblastoma.

Our Current Trials

At any given time we are sponsoring and collaborating on over 200 pediatric cancer and blood disorder clinical trials.